{"name":"Fore Biotherapeutics","slug":"fore-biotherapeutics","ticker":"","exchange":"","domain":"forebiotherapeutics.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTE1RSFNHWjhCY1Via1NqaV9UZUdxUHJhaU5sQkJlRXZyMjJUMWd4LWlTMDRjUlJVcVppU3R2eG50M0ZzZjVhakEtdlJwclFpUGR0TEpER1pTdlk5XzBEUnRnTFp1b0pZNHU5RmdZWTZINXk3ZWFXU3NDZ2laYw?oc=5","date":"2026-03-12","type":"deal","source":"PHILADELPHIA.Today","summary":"Chesterbrook's Persevere Therapeutics Raises $1.57M, Acquires Cancer Drug in Stealth Exit - PHILADELPHIA.Today","headline":"Chesterbrook's Persevere Therapeutics Raises $1.57M, Acquires Cancer Drug in Stealth Exit","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxOUnhTTkNtbGJKWl9ISTRMYzdNNkdCM3NtQnV6NUV0Y1U0cS1uT1I4SThDLThucDFlRXBleERaU2dEOGUwZW9QczBoVGdTVXhoWGhiM3c3OE9sNzJHMGlBeFd4dUhsUjJMWGlGRUx4MVZtX0tHcklXNmZ2X3M2UEc1RV85Z00yWTRmUWdWUXcyaGY2a0hoNzAw?oc=5","date":"2026-03-05","type":"pipeline","source":"The Pharma Letter","summary":"Roche survey highlights daily burden of diabetes - The Pharma Letter","headline":"Roche survey highlights daily burden of diabetes","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTE1nVE9HbXhwZkFuenRhLWJlLXl3VUl2T1VUMGRmY0V5SWJNMVBXWHpqMTA5SnNvZUF2ZVc3VW9sUFhkX1ZnZjdoeWMzNWhYaE9BTDFVYlBTRHpDSWtzWnV0UVB2QkZDanBqZTFBajZTNFIxQXhqaHdob29QQQ?oc=5","date":"2025-11-14","type":"pipeline","source":"pharmaphorum","summary":"Medicxi raises €500m for latest biotech fund - pharmaphorum","headline":"Medicxi raises €500m for latest biotech fund","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE5TMmdYdEN0Q2VwR2pRVGs5WVFMbGt5V0tqWC1UeVN2dklLaTFqUDBZaWVudktMRkVhdk5MVDhEcjJMMXE2cE5mQXNfdXpURzBTdFdraTRUaFVxeHBCcVkw?oc=5","date":"2025-07-01","type":"pipeline","source":"nature.com","summary":"Simplified kinetic modeling for predicting the stability of complex biotherapeutics - nature.com","headline":"Simplified kinetic modeling for predicting the stability of complex biotherapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxQTlpYYndPTjZjVUNFSkRra0E1YTZIRHZDVTRZRXlobHNxU2NVcVpJUXdLTnFyU0VJR0djLVFoV1dDZFR1R0syYWo4LXpaNUVvd1lVY0hNWnJxNHpVRXQzVGVSQ3N6dHUwQkY5ZGJWMmtocVEtTW5ocHluQTN4Mm12WS16Wmw?oc=5","date":"2025-05-22","type":"pipeline","source":"The Pharma Letter","summary":"Fore Biotherapeutics raises $38 million - The Pharma Letter","headline":"Fore Biotherapeutics raises $38 million","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_AFBVV95cUxQM1hfeHQtSnBQOFZRQ0JOZ0Vfc2Jtbk50REVDQ0RSZXJiTTZJTTA5UDFPdHRDT3V5QlNOUGduT2ExbHl0VFlWOENhWUlydkFZQ2NzNlhxQk1iSVlWNDRCbU16dnNzUlFxUWQ0cGZvS0FNRDh6Mmk0OGxJOXBBMDVXb3hTZGQxQkpTZDV5WU5vM1pJNDFfNGliV2xrNWlJUTBTYjhUV0hFY3pfVDZmSGNBbkZYVk91TXFCTWI2OVJGU1BGcXpWTHlIS1RScDJJNlAwZG9XMFEwdnhFMjVKUHBDdnJWcXlQNzFKbkl6bG9WaExMMXdkNEN5WThGa0s?oc=5","date":"2025-05-22","type":"pipeline","source":"Business Wire","summary":"FORE Biotherapeutics Raises $38 Million in Series D-2 Financing for the Continued Advancement of Plixorafenib - Business Wire","headline":"FORE Biotherapeutics Raises $38 Million in Series D-2 Financing for the Continued Advancement of Plixorafenib","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizgFBVV95cUxPaHp4S3otSjNHVS1iblMyTTNVam0wbW4td2hSNGg4MmNiNU9pbnBJLXB2V25tZDQ4OE1xUjdXaDN2UXRIMHREQ1FuOEE3eW5lV1BNMXBib0dfOXlxTTdWX01hQU5DN1lHT1J5M21Nc1hBY2hzcFlFcVdpQnU2NDJZRGxRQTRVcXF0aGU5cHcwSk5sV0pYSUl1SWdOYlpHX0xuUFVibDVuTXZjM3d1STdRVFZGSU9WM1ZCMGRMS2pudlppUjR2dzVwTEZSQ2tPUQ?oc=5","date":"2025-01-21","type":"regulatory","source":"reuters.com","summary":"US FDA puts clinical hold on Atara's trials for cancer cell therapies - reuters.com","headline":"US FDA puts clinical hold on Atara's trials for cancer cell therapies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAJBVV95cUxPb0NxWVRwWnN3NVRaQlJyWlhQdG5oR0tqRVNWM2xaWktkMmdwY1RaV2NxMHlUc3BlUThweFAtNFFjY2ptTEFqdFM4RGhRV2VoSUl1bm1Wd20yX0ZBS3FRc0JBMG02QldxRXhZWW1vTzhPekI4ODZaRkJZdzZCSU5VbWlQeTM2T0tXN014bFpqMDlzeFZvckdGSGdUYnRhMVhnMWlvWXdKMzFLQkZ5YWVPQjdtTEFKcnJxUFplRlpJaVVqMVE3ZjhzUXN3dk1RRFJGQnRFcHBOdzZaMjJjQ0daN1UtRTdsM0lhRTYxM1dtVVBHelB5NFBzUHp3MEdxUEhWYXBrdE9hVG8?oc=5","date":"2025-01-09","type":"pipeline","source":"BioSpace","summary":"FORE Biotherapeutics Highlights Recent Pipeline Achievements for its Targeted-Oncology Program and Provides Strategic Objectives for 2025 - BioSpace","headline":"FORE Biotherapeutics Highlights Recent Pipeline Achievements for its Targeted-Oncology Program and Provides Strategic Ob","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxNTklSeTEtODE3TkduSjRpaUlYUjhHN1RTX2ZnSXZzNW0xOVlPc3ZaYndyM0NHN19DMW5pTkRjZ3VUQm9WUF8tM21sX3B1TWppZXA4MTRmRUtGRVhkWkxrMzE3bV9WTVpFRVpPMElZRzAwTng1T2FhUWZZS0F0cjIySFFvVHFqVlpGcXhxeVl4M0liSGUwVUE1M3J6cWlnQ0d2bER1SklheXdwLW1YdE9EZmNpSVlabjdKMmlBVg?oc=5","date":"2024-10-10","type":"pipeline","source":"BioPharm International","summary":"Prioritizing Formulation Strategies for Temperature-Sensitive Biotherapeutics - BioPharm International","headline":"Prioritizing Formulation Strategies for Temperature-Sensitive Biotherapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxPUTBBUUtwQVVWV2c2aE1yWE9ZZ3hEM0NoU2ZWckF5ZG54azFNeENUTjFWVVQ1Z3kxQXpPcHJ0VTNiQlhnNzhId3pSV1BvNl9WTEVRUVlxR3FPOFd0cFd5N01XVXhjNi1FbU5fVHNkT2c0UjN3LVBSMFJrWWdjTE9ZYkRmSlVzR0pNZlo3djIwWGNUTTd6VHlKdlhmOXZ6WnYzXzV5elNob2RLa2NJM2J5VHRRbw?oc=5","date":"2024-08-15","type":"pipeline","source":"Medical Marketing and Media","summary":"The Escalator: Pfizer, Fore Biotherapeutics, Eversana and more - Medical Marketing and Media","headline":"The Escalator: Pfizer, Fore Biotherapeutics, Eversana and more","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxNWmNMbkFOeV9tb1Y0Z3V0NjFBMHFSVF8wMlhkTmxhblpMWm5YSGloc3RXYnJtQ0xMVG1KX3ZtSUdRQWtPaENhZzg1NFB6VEs1ZnJRRDFiODZ3eGd1Qnl5elM4anY5cG1XakVXZEZsbkV0X2NDMmdUc0FtMVRPS3AtUFlCdjMzRzcwSFJ3?oc=5","date":"2022-11-28","type":"pipeline","source":"The Lancet","summary":"Expanding access to biotherapeutics in low-income and middle-income countries through public health non-exclusive voluntary intellectual property licensing: considerations, requirements, and opportuni","headline":"Expanding access to biotherapeutics in low-income and middle-income countries through public health non-exclusive volunt","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxPa29fcDZSYWFQemRFY2dzZlJadFZqUWVhRVVMZGw5UnhjbUtmd1hWRkRvZWxJQWxqWjZjV0E3QmNfMl9wYVZiMzZWTDdOaGhOZHFxV0thRnNzN2ZHUHZBd1FUWmpZN2VUZ0RrS201Y0txSjRqMnBGUWVCQWVFcXJTbzVkMnJnQ3FYa2NYNWVTMW5YRVdOQ0lsanFmamt1VVNWVnEzby11aGRrZkdKQUF4cmtBOHNvbXY0Yk55M2JXRXpaQQ?oc=5","date":"2021-02-22","type":"pipeline","source":"Fierce Biotech","summary":"Novellus becomes Fore Biotherapeutics as it completes pivot from diagnostics to precision oncology - Fierce Biotech","headline":"Novellus becomes Fore Biotherapeutics as it completes pivot from diagnostics to precision oncology","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}